Legal Proceedings

EX-10.44 9 v79469ex10-44.txt EXHIBIT 10.44 EXHIBIT 10.44 *CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. October 18, 2001 Corixa Corporation 1124 Columbia Street Suite 200 Seattle, Washington 98104, U.S.A. Attention: Chairman RE: Collaboration Agreement Dated October 23, 1998 between Coulter Pharmaceutical, Inc. and SmithKline Beecham Corporation Dear Sir: This Letter Agreement sets forth our agreement that as to the matters set forth herein in connection with the Collaboration Agreement (the "Agreement"), executed as of October 23, 1998 by and between Coulter Pharmaceutical, Inc., a company incorporated under the laws of the State of Delaware, with its principal place of business at 600 Gateway Boulevard, South San Francisco, California 94080-7014, U.S.A. ("Coulter") which has been acquired by Corixa Corporation, a company incorporated under the laws of the State of Delaware, with its principal place of business at 1124 Columbia Street, Suite 200, Seattle, Washington 98104, U.S.A. ("Corixa"), and SmithKline Beecham Corporation (a GlaxoSmithKline Company), a company incorporated under the laws of the Commonwealth of Pennsylvania, with its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19101, U.S.A. ("GSK"), as amended to date, the parties hereto agree as follows. This Letter Agreement (the "Letter") is a binding agreement of Corixa and GSK. All terms used, but not defined, in this Letter shall have the respective meanings set forth in the Agreement. 1. [*]. 2. The parties hereby replace the second paragraph of Part B of the April 2000 Letter Amendment in its entirety with the following: "Subject to the MANUFACTURING DEVELOPMENT COSTS cap outlined above, GSK agrees that it shall pay Corixa one hundred percent (100%) of GSK's share of all invoices received from Corixa that are related to approved MANUFACTURING DEVELOPMENT COSTS and DEVELOPMENT COSTS, in each case within thirty (30) days following receipt of such invoice, provided that such invoices are sent to GSK with supporting documentation as described in Exhibit A to the Letter Agreement, dated October 18, 2001 between GSK and Corixa, which Exhibit A shall be incorporated in this Letter Agreement by this reference. In the event of any disagreement with respect to the amounts invoiced in accordance with the foregoing for either clinical or development services, the parties shall resolve - -------- * Confidential Treatment Requested. Page 1 such disagreement within the ninety (90) day period that follows GSK's receipt of the invoice that is the basis of such disagreement. If the parties determine that an amount is due GSK as a result of such resolution, such amount shall at Corixa's option either be credited against the amount payable by GSK to Corixa pursuant to the next fiscal quarter's invoice or shall be paid to GSK by Corixa within thirty (30) days following such resolution." All other terms and conditions of the Agreement shall remain in full force and effect. If Corixa agrees with the terms and conditions of this Letter, please have an appropriate representative of Corixa sign and date the enclosed duplicate of this Letter as indicated below and return it to GSK. Very truly yours, SMITHKLINE BEECHAM CORPORATION (a GlaxoSmithKline Company) By: /s/ Paul A. Holcombe, Jr. ------------------------------------- Title: Senior VP and General Counsel-US ---------------------------------- Date: October 18, 2001 ---------------------------------- AGREED TO AND ACCEPTED: CORIXA CORPORATION By: /s/ Steven Gillis ---------------------------------- Title: Chairman & CEO ------------------------------- Date: October 19, 2001 ------------------------------- Page 2